Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5779-5787

  De Vries, I Jolanda M ^a   Bernsen, Monique R ^a   Lesterhuis, W Joost ^a   Scharenborg, Nicole M ^a   Strijk, Simon P ^a   Gerritsen, Marie Jeanne P ^a   Ruiter, Dirk J ^a   Figdor, Carl G ^a   Punt, Cornelis J A ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MONOPHENOL MONOOXYGENASE; TETRAMER; TUMOR ANTIGEN; CANCER VACCINE; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MELANOMA; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; SKIN BIOPSY; SKIN INDURATION; SKIN TEST; STAINING; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; BIOPSY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; BIOPSY; CANCER VACCINES; DENDRITIC CELLS; FLOW CYTOMETRY; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 24944546501     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.478     Document Type: Article

References (34)

1. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
2. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
3. Schuler-Thurner B, Schultz ES, Berger TG, et al: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288, 2002
4. Toes RE, Ossendorp F, Offringa R, et al: CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753-756, 1999
5. Melief CJ, Van Der Burg SH, Toes RE, et al: Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177-182, 2002
6. De Vries IJ, Lesterhuis WJ, Scharenborg NM, et al: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091-5100, 2003
7. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243-251, 2001
8. Dhodapkar MV, Steinman RM, Krasovsky J, et al: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238, 2001
9. Figdor CG, de Vries IJ, Lesterhuis WJ, et al: Dendritic cell immunotherapy: Mapping the way. Nat Med 10:475-480, 2004
10. Romero P, Cerottini JC, Waanders GA: Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 4:305-312, 1998
11. Coulie PG, Karanikas V, Colau D, et al: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 98: 10290-10295, 2001
12. Altman JD, Moss PA, Goulder PJ, et al: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96, 1996
13. Rubio-Godoy V, Dutoit V, Rimoldi D, et al: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A 98:10302-10307, 2001
14. Thiel A, Scheffold A, Radbruch A: Antigen-specific cytometry: New tools arrived!. Clin Immunol 111:155-161, 2004
15. Lee PP, Yee C, Savage PA, et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685, 1999
16. Romero P, Dunbar PR, Valmori D, et al: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641-1650, 1998
17. Barnstable CJ, Bodmer WF, Brown G, et al: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: New tools for genetic analysis. Cell 14:9-20, 1978
18. Quaranta V, Walker LE, Pellegrino MA, et al: Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol 125:1421-1425, 1980
19. Balch CM, Cascinelli N: The new melanoma staging system. Tumori 87:S64-S68, 2001
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Thurner B, Roder C, Dieckmann D, et al: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1-15, 1999
22. De Vries IJ, Eggert AA, Scharenborg NM, et al: Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 25:429-438, 2002
23. Bakker AB, Schreurs MW, Tafazzul G, et al: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 62:97-102, 1995
24. Wolfel T, Schneider J, Meyer Zum Buschenfelde KH, et al: Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int J Cancer 57:413-418, 1994
25. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994
26. Topalian SL, Gonzales MI, Parkhurst M, et al: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965-1971, 1996
27. Li K, Adibzadeh M, Halder T, et al: Tumour-specific MHC-class-II- restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32-38, 1998
28. Bakker AB, Schreurs MW, de Boer AJ, et al: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994
29. Brossart P, Wirths S, Stuhler G, et al: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108, 2000
30. Lau R, Wang F, Jeffery G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001
31. Valmori D, Dutoit V, Schnuriger V, et al: Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 168:4231-4240, 2002
32. Speiser DE, Lienard D, Pittet MJ, et al: In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines: A comparison to virus-specific T cells. Eur J Immunol 32:731-741, 2002
33. Vermorken JB, Claessen AM, van Tinteren H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353:345-350, 1999
34. Hersey P, Menzies SW, Halliday GM, et al: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125-134, 2004